DrugPatentWatch Database Preview
VIEKIRA PAK (COPACKAGED) Drug Profile
When do Viekira Pak (copackaged) patents expire, and when can generic versions of Viekira Pak (copackaged) launch?
Viekira Pak (copackaged) is a drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this drug.
The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir profile page.
Summary for VIEKIRA PAK (COPACKAGED)
| US Patents: | 18 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIEKIRA PAK (COPACKAGED) |
| DailyMed Link: | VIEKIRA PAK (COPACKAGED) at DailyMed |
-patent-expirations.png "VIEKIRA PAK (COPACKAGED) drug patent expirations")
Generic Entry Opportunity Date for VIEKIRA PAK (COPACKAGED)
Generic Entry Date for VIEKIRA PAK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for VIEKIRA PAK (COPACKAGED)
Expired US Patents for VIEKIRA PAK (COPACKAGED)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for VIEKIRA PAK (COPACKAGED)
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010030359 | ➤ Try a Free Trial |
| South Korea | 20140056195 | ➤ Try a Free Trial |
| Hong Kong | 1170739 | ➤ Try a Free Trial |
| Slovenia | 2203431 | ➤ Try a Free Trial |
| United Kingdom | 201411074 | ➤ Try a Free Trial |
| Canada | 2938547 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for VIEKIRA PAK (COPACKAGED)
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015 00013 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150119 |
| 0150019 00156 | Estonia | ➤ Try a Free Trial | PRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015 |
| 0150015 00143 | Estonia | ➤ Try a Free Trial | PRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015 |
| 2017 00049 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728 |
| 2017000074 | Germany | ➤ Try a Free Trial | PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2017033 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
